This website is intended for UK healthcare professionals only. Not a UK healthcare professional? Click here.
THINK BEYOND LDL-C TARGETS WITH PROVEN CV RISK REDUCTION
When statins and ezetimibe are not enough, prescribe NILEMDO® (bempedoic acid) or switch ezetimibe to NUSTENDI® (bempedoic acid and ezetimibe) to help your eligible patients reduce their CV risk.1–3
Concomitant use of NUSTENDI®/NILEMDO® with simvastatin >40 mg daily is contraindicated; please refer to the relevant SmPC for more information.1,2
*For study results with respect to effects on LDL-C, CV events and populations studied see section 5.1 of the relevant SmPC.1,2
CV risk reduction estimation for ezetimibe in primary prevention patients has not been established. Evidence for the use of NUSTENDI® in patients at high risk of ASCVD is only available for the lipid-lowering effect (see section 5.1 of the NUSTENDI® SmPC).2
Think beyond statins + ezetimibe with NUSTENDI®: One tablet combining two complementary LDL-C lowering agents2
Concomitant use with simvastatin >40 mg daily is contraindicated; please refer to the SmPC for more information.2
Bempedoic acid 180 mg/ ezetimibe 10 mg fixed dose for all eligible patients2
Oral, once daily, with or without food2
Can be initiated in your eligible primary and secondary prevention patients2,4
For patients taking a bile acid sequestrant concomitantly, dosing of NUSTENDI® should occur either at least 2 hours before or at least 4 hours after administration of a bile acid sequestrant.2
Liver function tests should be performed at initiation of NUSTENDI® therapy and treatment with NUSTENDI® should be discontinued if an increase in transaminases >3x ULN persists.2
Please refer to the NUSTENDI® SmPC prior to prescribing.2
Think beyond statins with NILEMDO®1
Concomitant use with simvastatin >40 mg daily is contraindicated; please refer to the SmPC for more information.1
Bempedoic acid 180 mg for all eligible patients1
Oral, once daily, with or without food1
Can be initiated in your eligible primary and secondary prevention patients1
Liver function tests should be performed at initiation of NILEMDO® therapy and treatment with NILEMDO® should be discontinued if an increase in transaminases >3x ULN persists.1
Please refer to the NILEMDO® SmPC prior to prescribing.1
Discover more
Latest expert opinions
Considerations for CVD risk reduction in patients with diabetes and elevated LDL-C
Join leading experts as they discuss key considerations for managing hypercholesterolaemia and mixed dyslipidaemia in patients with diabetes, with a focus on reducing their heightened CV risk through effective lipid-lowering therapies.
Dr. Patrick Holmes and Beverley Bostock
8 mins
Managing CVD risk in patients with diabetes and elevated LDL-C
Adult patients with diabetes are 2–3 times more likely to develop CVD and approximately twice as likely to die from heart disease or stroke compared to those without diabetes.5
Cholesterol management is one vital component of a holistic approach to CV risk reduction in diabetes care. When treating patients with diabetes, the greatest reductions in CV risk and mortality are seen with combined long-term risk factor management of blood pressure, HbA1c and lipids.6,7
Even after LLT, ≥60% of patients with diabetes do not reach guideline-recommended ESC/EAS 2019 LDL-C goals, therefore remaining at increased risk of CVD.8,*
Join leading experts, Dr. Patrick Holmes and Beverley Bostock, as they delve into key considerations for managing hypercholesterolaemia and mixed dyslipidaemia in patients with diabetes, with a focus on reducing their heightened CV risk through effective lipid-lowering therapies.
In this video, they review current practices for managing patients with diabetes, address common patient concerns and barriers to initiating LLT, and discuss the available treatment options, highlighting the importance of selecting the right therapy for each patient.
Explore the efficacy data for NUSTENDI® and NILEMDO®
*Patients receiving combination therapy of statin + ezetimibe (N=4,516).8
References
- NILEMDO® Summary of Product Characteristics.
- NUSTENDI® Summary of Product Characteristics.
- Nissen SE, et al. N Engl J Med. 2023;338(15):1353–1364.
- National Institute for Health and Care Excellence. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [TA694]. Available at: https://www.nice.org.uk/guidance/TA694 Accessed: September 2025.
- British Heart Foundation. UK Factsheet. January 2025. Available at: https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf Accessed: September 2025.
- NHS. NHS RightCare Pathway: Diabetes. Available at https://www.england.nhs.uk/rightcare/wp-content/uploads/sites/40/2018/07/nhs-rightcare-pathway-diabetes.pdf Accessed: September 2025.
- Yudkin JS, et al. Diabetologia. 2010;53:2079–2085.
- Morieri ML, et al. Cardiovasc Diabetol. 2020;19:190.
Abbreviations
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; HbA1c, glycated haemoglobin; HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; SmPC, Summary of Product Characteristics; ULN, upper limit of normal.
Job code: UK/BIL/08/25/0002|Date of preparation: September 2025